ADRI (Alzheimer's Disease Risk Index)

Power-Stem's patented inspection technology utilizes advanced Enzyme-Linked Immunosorbent Assay (ELISA) tools to accurately measure the concentration of oxidative proteins disorder (GAPDH) associated with neuronal decay, providing a precise assessment of the risk for Alzheimer's disease.

With a clinical accuracy rate of 95.74% and high sensitivity in detecting this chronic neurological disorder, the ADRI inspection patent has received global patent authorization, being a trailblazer in Alzheimer's disease analysis.

Beauty-Stem Biomedical_Taiwan Patent

Taiwan Patent

Beauty-Stem Biomedical_Japan Patent

Japan Patent

Beauty-Stem Biomedical_China Patent

China Patent

Beauty-Stem Biomedical_US Patent

US Patent

Beauty-Stem Biomedical_EU Patent

EU Patent